
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is a promising biotechnology company with a clear focus on precision oncology therapies for various types of cancer. Their pipeline products, particularly PRMT5 and CoREST, have shown promising results in clinical trials, especially in combination with other drugs. The company's potential for success is further strengthened by its partnerships and collaborations, and it operates in a highly competitive market. The recent positive clinical trial data and plans for Phase 3 development have raised our confidence in the company's potential and we have revised our outlook accordingly.
Bears say
Tango Therapeutics is currently not in a favorable financial position, as it requires significant capital to conduct clinical trials and may need to access dilutive and non-dilutive financing. The company also faces potential competition from larger players in the crowded field of KRAS inhibitors, which could hinder its success in the market. Additionally, the recent change in development strategy for its lead product vopimetostat raises concerns about its potential as a monotherapy and in combination therapy with RAS inhibitors. Overall, there are significant financial and competitive risks associated with investing in Tango Therapeutics, making a negative outlook on its stock justified.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares